What Is Mydayis XR? Uses, Dosage, and What You Need to Know in 2026

Mydayis XR is one of the longest-acting ADHD medications on the market today. If you've heard the name but aren't sure how it works or whether it might be right for you, this guide covers everything you need to know — from what it is to how much it costs to how it compares to better-known medications like Adderall XR and Vyvanse.

What Is Mydayis XR?

Mydayis XR (generic name: mixed salts of a single-entity amphetamine product, extended-release) is a prescription stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). It belongs to the class of drugs called central nervous system (CNS) stimulants.

Originally developed by Shire (now part of Takeda Pharmaceuticals) and FDA-approved on June 20, 2017, Mydayis was designed specifically to address a gap in ADHD treatment: providing reliable symptom coverage that extends well into the evening. It is approved for patients 13 years and older.

What makes Mydayis unique is its triple-bead delivery system. Each capsule contains three types of drug-releasing beads — one immediate-release and two delayed-release — that together provide up to 16 hours of symptom control from a single morning dose.

What Is Mydayis XR Used For?

Mydayis XR is FDA-approved exclusively for the treatment of ADHD in patients aged 13 and older. It is NOT approved for children under 13.

It's particularly well-suited for patients who:

• Find that shorter-acting medications wear off too early — leaving them unfocused in the afternoon or evening
• Need coverage for homework, second-shift work, evening responsibilities, or parenting
• Want to avoid taking a booster dose in the afternoon
• Have tried Adderall XR or Vyvanse and found them effective but too short-lasting

Mydayis XR Dosage: Strengths and How to Take It

Mydayis XR comes as an extended-release capsule in four strengths: 12.5 mg, 25 mg, 37.5 mg, and 50 mg.

For adolescents (ages 13–17): Starting dose is 12.5 mg once daily in the morning. Maximum recommended dose is 25 mg per day.

For adults (ages 18+): Starting dose is 12.5 mg once daily in the morning. Dose may be increased by 12.5 mg increments weekly up to a maximum of 50 mg per day.

Key administration rules:

• Take once daily in the morning upon waking — the 16-hour duration means an afternoon dose could keep you up all night
• Can be taken with or without food, but consistently one way or the other (food can affect absorption)
• Swallow the capsule whole, or open and sprinkle the entire contents on a spoonful of applesauce — consume immediately without chewing
• Do not split, crush, or chew the capsule or its beads — this disrupts the time-release mechanism
• If you miss a dose, do NOT take it later in the day — skip it and resume the next morning

How Does Mydayis XR Compare to Adderall XR and Vyvanse?

All three medications are amphetamine-based stimulants used for ADHD. Here's how they differ:

• Duration: Adderall XR lasts 10–12 hours. Vyvanse lasts 12–14 hours. Mydayis XR lasts up to 16 hours.
• Release system: Adderall XR uses a two-bead system. Mydayis XR uses a triple-bead system with three distinct release phases.
• Age approval: Adderall XR is approved for ages 6+. Vyvanse is approved for ages 6+. Mydayis is approved for ages 13+.
• Generic available: Yes — all three now have FDA-approved generics.
• Cost: Brand Mydayis costs $345–$466 per month at retail. Generic with a coupon can be as low as $92–$150 per month.

Who Should NOT Take Mydayis XR?

Mydayis is not appropriate for everyone. Your doctor will not prescribe it if you have:

• Known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, or coronary artery disease
• Moderate to severe hypertension (uncontrolled high blood pressure)
• Hyperthyroidism or glaucoma
• Taken an MAOI antidepressant within the past 14 days (serious interaction risk)
• Severe kidney disease (end-stage renal disease)
• A history of substance use disorder (requires careful evaluation)

Availability and Cost in 2026

Mydayis XR is a Schedule II controlled substance, and like other amphetamine-based ADHD medications, it has been affected by supply shortages. The amphetamine shortage that began in October 2022 continues to affect availability in 2026, though the situation has improved following DEA quota increases in late 2025.

Because Mydayis is less commonly prescribed than Adderall XR, pharmacy stock can be limited and inconsistent. Medfinder can help you locate which pharmacies near you currently have it in stock. For more tips, read our full guide on finding Mydayis in stock near you.